Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma

Stephen M. Ansell, Anne J. Novak, Steven Ziesmer, Tammy Price-Troska, Betsy Laplant, Stacey R. Dillon, Thomas E. Witzig

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene. Am. J. Hematol.

Original languageEnglish (US)
Pages (from-to)71-73
Number of pages3
JournalAmerican journal of hematology
Volume84
Issue number2
DOIs
StatePublished - Feb 2009

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this